Mesoblast (MESO) Cash from Investing Activities Growth (1y) (2017 - 2023)

Mesoblast (MESO) Cash from Investing Activities Growth (1y) (2017 - 2023) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Growth (1y) (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 90.55%
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 91.53%
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn -
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 25.90%
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn 7,936.68%
7 Royalty Pharma 33.72 Bn 35.84 Bn - 26.37%
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn -157.08%
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn -89.24%
10 Mesoblast 2.01 Bn 1.87 Bn - -

Historic Data

Download Data
DateValue
Jun 30, 2023 134.04%
Mar 31, 2023 148.21%
Dec 31, 2022 -13.33%
Sep 30, 2022 -105.05%
Jun 30, 2022 78.92%
Mar 31, 2022 94.02%
Dec 31, 2021 92.63%
Sep 30, 2021 -22.22%
Jun 30, 2021 88.06%
Mar 31, 2021 -35.06%
Dec 31, 2020 11.33%
Sep 30, 2020 67.98%
Jun 30, 2020 -134.09%
Mar 31, 2020 -670.00%
Dec 31, 2019 -528.77%
Sep 30, 2019 -548.72%
Jun 30, 2019 -83.03%
Mar 31, 2019 -143.24%
Dec 31, 2018 -35.19%
Sep 30, 2018 93.77%